Inrozol

Itraconazole, the active ingredient in Inrozol, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of serious fungal infections in adults and children when prescribed by a qualified healthcare professional.

GNH USA supplies Inrozol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent batch release and regulatory support across multiple markets.

Itraconazole is an azole antifungal used to treat systemic mycoses.

Blastomycosis: treatment of systemic infection caused by Blastomyces dermatitidis. Histoplasmosis: therapy for disseminated disease due to Histoplasma capsulatum. Aspergillosis: management of invasive infection caused by Aspergillus species. Candidiasis: control of severe or refractory Candida infections.

Itraconazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Rash or itching

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Cardiac failure or QT prolongation

When prescribing itraconazole, several safety considerations are recommended. - Liver monitoring: baseline and periodic liver function tests are recommended. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Cardiac risk: use cautiously in patients with heart failure or arrhythmias. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Itraconazole interacts with several drug classes; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, ritonavir) – may raise itraconazole levels. - Certain statins (simvastatin, lovastatin) – increased risk of myopathy. - Ergot alkaloids – can cause severe vasospasm.

Moderate Interactions (Monitor Closely): - Oral contraceptives – possible reduced effectiveness. - Warfarin – enhanced anticoagulant effect. - Antifungal combination therapy – monitor for additive toxicity.